secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2026-05-26T12:30:22+00:00
Accession:  0001493152-26-025172
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma announces discovery of pan-viral inhibitors with <50 nM potency against hantavirus
--------------------------------------------------------------------------------

- Novel pan-viral inhibitors target L-protein of Andes hantavirus; IC50 <50 nM against hantaan virus in vitro.
- Company expanding platform from CDI-988 (Phase 1b norovirus) to hantavirus, bunyavirus, influenza.
- No approved treatments or vaccines for hantaviruses; Andes strain linked to recent cruise ship outbreak with 3 deaths.
- Plans to evaluate activity against Andes hantavirus replication enzyme and explore partnerships.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315226025172/0001493152-26-025172-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315226025172/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-025172

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer